Wendy Diller

Senior Writer/Market Analyst

20 Years of Experience

About

Wendy writes on the medical devices and clinical diagnostics sectors, where she focuses on orthopedics/spine, molecular diagnostics and personalized medicine, clinical genomics, womens’ health/ femtech, and reimbursement/commercial strategy and innovation related to these specialties. She welcomes and encourages ideas and input from members of the MedTech Strategist Community.

Her career spans more than 20+ years as a top writer and manager focused on qualitative analysis of the global life sciences industry. She is Chair of Young Women in Bio Metro NY, an organization devoted to encouraging secondary students in the NY area to pursuit STEM careers and on the board of the Columbia Business School of Alumni Club NY

Specialties
Publications
Articles from Wendy Diller:
Read all from this author
Business Strategies

Minimally Residual Disease Testing Is Gaining Traction

  • 2025-10-02 00:00:00.0
  • Wendy Diller
  • MedTech Strategist

Investors in diagnostics have focused their attention on liquid biopsy technologies for early detection of cancer and screening applications, but companies are seizing minimal residual disease (MRD) testing as a near-term opportunity. Strategies for implementation are a work in progress for all stakeholders—payors, patients, providers, and regulators.

Read Article